Montani and colleagues found that ATM-depletion can sensitize breast cancer cells to PARP inhibition thus PARP inhibition could be of benefit in patients with low ATM protein expression/activity such as would be seen in heterozygous carriers of germline ATM mutation11. The gene discussed is PARP1; the disease is breast cancer.